The Randomized OPTIMAL-ACT Trial

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.

Also called NCT03772613

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 180 participants (enrolled count) (from the registry)
Sponsor
  • Mayo Clinic Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03772613
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03772613. Randomized; double masking; primary purpose treatment. Start 2019-02-08 (actual); primary completion 2021-10-25 (actual). Results posted on 2023-04-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Randomized OPTIMAL-ACT Trial
Condition
Ischemic Heart Disease
Condition
Anticoagulant-induced Bleeding
Condition
Coronary Syndrome
Intervention (Drug)
Unfractionated heparin
Lead sponsor
Mayo Clinic (class: other)

Record details

Record id
cardio:ct-nct03772613
Content hash
7365b8b6c84472ce4521e2ec13caa18f13d04dac372139fda6da1ca0a4f5390c